Organism group |
Effect | |
amphibian | suspected no endocrine effect No inhibition of progesterone-induced oocyte maturation |
Show study |
amphibian | Effect on estrogen Inhibition of [3H]estradiol binding to ER |
Show study |
amphibian | Effect on estrogen Induction of VTG mRNA |
Show study |
amphibian | Effect on estrogen Increased number of female phenotypes |
Show study |
crustacean | suspected endocrine effect Stimulated ovarian maturation, measured as an increased egg production rate |
Show study |
fish | Effect on estrogen Induction of vitellogenesis |
Show study |
fish | Effect on estrogen 100% female sex ratio |
Show study |
fish | Effect on estrogen Induction of testis-ova |
Show study |
fish | Effect on estrogen Induction of vitelllogenesis |
Show study |
fish | Effect on estrogen 70.2-106 痢/l: increased plasma VTG concentrations (not significant) |
Show study |
fish | Effect on estrogen 556 痢/l: significant induction of vitellogenesis |
Show study |
fish | Effect on estrogen Significantly decreased number of eggs and hatchings |
Show study |
fish | Effect on estrogen Approximately 300-fold increases in plasma VTG levels |
Show study |
fish | suspected no endocrine effect Increased HSI |
Show study |
mammalian | Effect on estrogen RBA compared to radiolabeled 17-beta-estradiol (%): 0.01 |
Show study |
mammalian | Effect on estrogen RBA compared to radiolabeled 17-beta-estradiol (%): 0.01 |
Show study |
mammalian | Effect on estrogen Inhibition of tritiated 17-beta-estradiol binding to ER |
Show study |
mammalian | Effect on estrogen Potency relative to 17-beta-estradiol: 0.0001 |
Show study |
mammalian | suspected no endocrine effect No significant displacement of T4 from transthyretin |
Show study |
mammalian | Effect on estrogen Induction of estrogen-mediated gene transcription |
Show study |
mammalian | Effect on estrogen Induction of estrogen-mediated gene transcription |
Show study |
mammalian | Effect on estrogen 1 g/kg: increased peroxidase activity |
Show study |
mammalian | suspected no endocrine effect 10 痢 - 100 mg: no evidence for estrogenic activity |
Show study |
mammalian | Effect on estrogen Inhibition of tritiated 17-beta-estradiol binding to ER |
Show study |
mammalian | Effect on estrogen Relative binding affinity: 0.00013 |
Show study |
mammalian | Effect on estrogen Inhibition of tritiated 17-beta-estradiol binding to ER |
Show study |
mammalian | Effect on estrogen Relative binding affinity: 0.000013 |
Show study |
mammalian | Effect on estrogen Induction of cell proliferation |
Show study |
mammalian | Effect on estrogen Stimulation of transcriptional activity of ER |
Show study |
mammalian | Effect on estrogen Increased uterus weight |
Show study |
mammalian | Effect on estrogen Increased uterus weight |
Show study |
mammalian | Effect on estrogen 600-800 mg/kg: premature vaginal opening |
Show study |
mammalian | Effect on estrogen Calculated log RBA: -1.14 |
Show study |
mammalian | Effect on estrogen Calculated log RBA: -0.18 |
Show study |
mammalian | Effect on estrogen Predicted log RBA: -1.16 |
Show study |
mammalian | Effect on estrogen Predicted log RBA: -0.52 |
Show study |
mammalian | suspected endocrine effect Reduction in efferent duct epithelial cell height |
Show study |
mammalian | Effect on estrogen Inhibition of fluorescent ligand ES1 binding to ER |
Show study |
mammalian | Effect on estrogen RBA compared to estradiol: 0.04% |
Show study |
mammalian | Effect on estrogen Induction of proliferation (full agonist) |
Show study |
mammalian | Effect on estrogen Relative potency to 17-beta-estradiol: 0.01% |
Show study |
mammalian | Effect on estrogen Increased PR concentration |
Show study |
mammalian | Effect on estrogen Induction of 17-beta-estradiol-mediated gene expression |
Show study |
mammalian | Effect on estrogen Relative potency to 17-beta-estradiol: 0.1% |
Show study |
mammalian | Effect on estrogen RBA compared to 17-beta-estradiol: 0.056% |
Show study |
mammalian | Effect on estrogen Induction of cell proliferation |
Show study |
mammalian | Effect on estrogen Induction of estrogen-dependent transcription |
Show study |
mammalian | Effect on estrogen Dose dependent tumor development |
Show study |
mammalian | Effect on estrogen Induction of ERalpha-mediated transcription |
Show study |
mammalian | Effect on estrogen 1-100 nM in combination with 10 nM 17-beta-estradiol: agonist |
Show study |
mammalian | Effect on estrogen 1 然 in combination with 10 nM 17-beta-estradiol: antagonist |
Show study |
mammalian | Effect on estrogen Induction of ERalpha-mediated transcription |
Show study |
mammalian | Effect on estrogen Combination with 10 nM 17-beta-estradiol: agonist |
Show study |
mammalian | Effect on estrogen Induction of ERalpha-mediated transcription |
Show study |
mammalian | suspected no endocrine effect No induction of PXR-mediated transcription |
Show study |
mammalian | suspected endocrine effect Increased CYP3A1 mRNA expression |
Show study |
mammalian | Effect on estrogen Activation of ERalpha |
Show study |
mammalian | Effect on estrogen Potency compared to 17-beta-estradiol: 0.038 |
Show study |
mammalian | Effect on estrogen Activation of ERalpha |
Show study |
mammalian | Effect on estrogen Increased peroxidase activity (estrogen-responsive) |
Show study |
mammalian | Effect on estrogen Increased PR levels (estrogen-responsive) |
Show study |
mammalian | suspected no endocrine effect No effect on reproductice organs weights |
Show study |
mammalian | suspected no endocrine effect No effect on reproductice organs weights |
Show study |
mammalian | suspected no endocrine effect No effect on reproductice organs weights |
Show study |
mammalian | suspected endocrine effect Altered expression and activities of male-specific cytochrome P450 isoforms |
Show study |
mammalian | Effect on estrogen Dose-dependent uterotrophic activity |
Show study |
mammalian | Effect on estrogen 128-250 mg/kg: dose-dependent pituitary gland hypertrophy |
Show study |
mammalian | Effect on pituitary hormone 128-250 mg/kg: dose-dependent hyperprolactinaemia |
Show study |
mammalian | Effect on estrogen Increased risk for breast cancer (significantly dependent on duration of exposure) |
Show study |
mammalian | Effect on estrogen Increased mean uterus wet weight (EC50 = 0.72 mg/day) |
Show study |
mammalian | Effect on estrogen 2 mg/day: increased luminal epithelial height and thickness of stromal and myometrial layers |
Show study |
mammalian | suspected no endocrine effect Female offspring: no apparent adverse effects on pubertal development and reproductive functions |
Show study |
mammalian | suspected no endocrine effect Male offspring: no significant effects on reproductive organ weights and micromorphology |
Show study |
mammalian | Effect on estrogen Induction of cell proliferation |
Show study |
mammalian | Effect on estrogen Additivity in combination with 4-tert-octylphenol (0.05 然) and technical 4-nonylphenol (0.05 然) |
Show study |
mammalian | Effect on estrogen Partial additivity in combination with benzyl-n-butylphtalate (2 然) and 4-hydroxybiphenyl (1 然) |
Show study |
mammalian | Effect on estrogen Dose-dependent induction of cell proliferation (RPE > 70%) |
Show study |
mammalian | Effect on estrogen EEQ: 58-70 ng/l |
Show study |
mammalian | Effect on estrogen Quantified phenolic compounds: 0.72-0.83% of total estrogenic activity |
Show study |
mammalian | Effect on estrogen Dose-dependent induction of cell proliferation (RPE: 40%) |
Show study |
mammalian | Effect on estrogen EEQ: 6 ng/l |
Show study |
mammalian | Effect on estrogen Quantified phenolic compounds: 1.4-4.3% of total estrogenic activity |
Show study |
mammalian | Effect on estrogen Induction of cell proliferation |
Show study |
mammalian | Effect on estrogen RPE: 97.4% |
Show study |
mammalian | suspected endocrine effect Sex-specific effects on nonsocial behavior |
Show study |
mammalian | suspected endocrine effect Sex-specific effects on nonsocial behavior |
Show study |
mammalian | suspected endocrine effect Decreased plasma free testosterone levels |
Show study |
mammalian | suspected endocrine effect Multinucleated giant cells in the seminiferous tubules of the testis |
Show study |
mammalian | suspected endocrine effect IC50 for [3H]testosterone displacement from SHBG: 51 然 |
Show study |
mammalian | suspected endocrine effect IC50 for [3H]17-beta-estradiol displacement from SHBG: 13.6 然 |
Show study |
mammalian | suspected endocrine effect 100 然: 30% increase in non-SHBG-bound testosterone |
Show study |
mammalian | suspected endocrine effect 100 然: 16% increase in non-SHBG-bound 17-beta-estradiol |
Show study |
mammalian | Effect on estrogen RTA for ERalpha compared to radiolabeled 17-beta-estradiol (%): 50 |
Show study |
mammalian | Effect on estrogen RTA for ERbeta compared to radiolabeled 17-beta-estradiol (%): 41 |
Show study |
yeast | Effect on estrogen Induction of hER-mediated transcription |
Show study |
yeast | Effect on estrogen Relative potency to 17-beta-estradiol: 0.0001 |
Show study |
yeast | Effect on anti-androgen Inhibition of DHT activity (dose-dependent) |
Show study |
yeast | Effect on estrogen Induction of ER-mediated gene expression |
Show study |
yeast | Effect on estrogen Induction of ER-mediated gene expression |
Show study |
yeast | Effect on estrogen Induction of ER-mediated gene expression |
Show study |
yeast | Effect on estrogen Induction of hER dimerization (101.2% of maximal estradiol response) |
Show study |
yeast | Effect on estrogen Induction of hER-dependent gene transcription (62.4% of maximal estradiol response) |
Show study |
yeast | Effect on estrogen Inhibition of tritiated estradiol binding to ER |
Show study |
yeast | suspected no endocrine effect No induction of PXR-mediated transcription |
Show study |
yeast | Effect on estrogen Induction of ER-mediated transcription |
Show study |